Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.3550 (1.06%) ($14.1000 - $14.5300) on Thu. Aug. 27, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.69% (three month average) | RSI | 34 | Latest Price | $14.3550(1.06%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.4% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.6% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.845% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) UNG(-4%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.845% (StdDev 3.69%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $10.27(-28.46%) | Inflection Point | Yes | Resistance Level | $14.72 | 5 Day Moving Average | $14.43(-0.52%) | 10 Day Moving Average | $14.55(-1.34%) | 20 Day Moving Average | $14.72(-2.48%) | To recent high | -9.7% | To recent low | 31.3% | Market Cap | $3.707b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |